Bayer's China Boost for Kerendia Can't Halt Stock's Slide Below Key Technical Level

Bayer gains China approval for heart drug Kerendia, but stock falls below 50-day moving average on overbought signals and headwinds.

Bayer secured a major regulatory victory in China on Friday, yet the stock closed in the red, breaching a closely watched technical threshold. The shares ended the session at €38.39, down 1.97%, and slipped beneath the 50-day moving average of €38.91 — a move chartists interpret as a short-term warning signal.

The expanded approval from China's National Medical Products Administration (NMPA) clears finerenone, sold under the brand name Kerendia, for adult patients with symptomatic chronic heart failure and a left ventricular ejection fraction of at least 40%. The drug was already approved in China for chronic kidney disease linked to type 2 diabetes. The new indication rests on the phase 3 FINEARTS-HF trial, which enrolled roughly 6,000 patients. The study met its primary composite endpoint of cardiovascular death and first and recurrent heart failure events, showing a significant reduction versus placebo regardless of background therapies.

The market opportunity is substantial. Globally, more than 64 million people suffer from heart failure. In China alone, over 13 million patients are affected, with about 60% having an ejection fraction of 40% or higher — precisely the population now eligible for Kerendia. The drug has already become a growth engine for Bayer: first-quarter 2026 Kerendia revenues surged 84.2% on a currency- and portfolio-adjusted basis, driven by the U.S. and China. Fellow pipeline product Nubeqa also posted a 57.1% quarterly gain. Yet the broader pharma division slipped slightly year on year, weighed by patent losses on older blockbusters like Xarelto and generic pressure on Eylea.

So why did the market shrug off the positive news? Technical factors are partly to blame. The breach of the 50-day moving average came as the relative strength index sat at 70.3 — territory that suggests the stock was overbought and vulnerable to a pullback. The breakdown opens the door to further selling, with the next support level around €38.50. Should that fail, the 200-day moving average at €35.39 looms as the next meaningful floor, roughly €3 lower. Conversely, a quick recapture of the 50-day average could brighten the short-term picture.

Investor caution also reflects the broader fundamental headwinds Bayer continues to face. The unresolved glyphosate litigation in the U.S. remains a persistent overhang. Expiring patents and a slow deleveraging process add to the pressure. On the pipeline front, the OCEANIC-STROKE study for Asundexian delivered a solid data point — the drug reduced ischemic strokes compared with placebo without increasing major bleeding — but its commercial potential is still unproven.

Analyst sentiment offers little comfort to the bears. DZ Bank, Barclays, JPMorgan and UBS all carry positive ratings on Bayer — ranging from "Buy" to "Overweight" — with only Deutsche Bank sticking at "Hold." For now, the chart is telling a different story to the sell-side consensus.

The stock’s 12-month performance still shows a roughly 58% gain, but it remains almost 22% below its 52-week high of €49.17. Bayer confirmed its full-year 2026 guidance on May 12, forecasting group revenue between €44.5 billion and €46.5 billion and EBITDA before special items of €9.4 billion to €9.9 billion. Whether younger products like Kerendia and Nubeqa can shield the top line from the drag of older franchises will determine if those targets are met — and whether the technical breakdown proves to be a buying opportunity or the start of a deeper correction.